Sab BiotherapeuticsSABS
13F holders, Q3 2025 (September 30)34holders +9
13new positions
4sold out
1famous investor
$2.01avg. 13F price*
At the end of Q3 2025, 34 institutions reported holding Sab Biotherapeutics Inc. (SABS) in their 13F filings, up 9 from Q2 2025. 13 opened new positions and 4 sold out. The largest holders were Vivo Capital, LLC ($23.0M), Commodore Capital LP ($8.8M) and Ra Capital Management, L.P. ($8.8M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Sab Biotherapeutics Inc.
- CUSIP
- 78397T202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 13 | $48.7M |
| Exits | 4 | $58K |
All 13F filers, Q2 2025 → Q3 2025: 26,133,936 shares bought and 33,872 shares sold, net +26,100,064 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 34 holders
| Vivo Capital, LLC | 1.85% | New | 11,420,000 | $23.0M |
| Commodore Capital LP | 0.43% | New | 4,401,500 | $8.8M |
| Ra Capital Management, L.P. | 0.11% | New | 4,401,500 | $8.8M |
| Woodline Partners LP | 0.03% | New | 2,850,881 | $5.7M |
| Sessa Capital IM, L.P. | 0.11% | Add +379.5% | 2,198,457 | $4.4M |
| BVF Inc. | 0.08% | Add +1.6% | 932,697 | $1.9M |
| Sphera Funds Management LTD. | 0.27% | New | 566,395 | $1.1M |
| Vanguard Group Inc. | 0.00% | Add +29.5% | 365,753 | $735K |
| HB Wealth Management, LLC | 0.00% | New | 307,500 | $618K |
| AWM Investment Company, Inc. | 0.04% | New | 200,000 | $402K |
| Geode Capital Management, LLC | 0.00% | Add +1.1% | 85,718 | $172K |
| Renaissance Technologies | 0.00% | Add +632.9% | 80,840 | $162K |
| Pathstone Holdings, LLC | 0.00% | No change | 50,650 | $102K |
| Virtu Financial LLC | 0.00% | New | 19,982 | $40K |
| NorthCoast Asset Management LLC | 0.00% | No change | 19,201 | $39K |
| First PREMIER Bank | 0.01% | No change | 18,986 | $38K |
| Dimensional Fund Advisors LP | 0.00% | New | 15,781 | $32K |
| ADAR1 Capital Management, LLC | 0.00% | New | 15,000 | $30K |
| UBS Group AG | 0.00% | Add +24.1% | 13,221 | $27K |
| Kestra Advisory Services, LLC | 0.00% | No change | 11,930 | $24K |
| Northern Trust Corp. | 0.00% | No change | 11,387 | $23K |
| Goldman Sachs Group Inc. | 0.00% | New | 11,221 | $23K |
| Caxton Corp. | 0.10% | New | 10,935 | $22K |
| BlackRock, Inc. | 0.00% | Reduce -9.5% | 6,339 | $13K |
| Osaic Holdings, Inc. | 0.00% | Reduce -2.3% | 4,824 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +114.9% | 1,560 | $3K |
| Citigroup Inc. | 0.00% | New | 832 | $2K |
| MAI Capital Management | 0.00% | No change | 217 | $437 |
| GS Investments, Inc. | 0.00% | No change | 200 | $402 |
| Morgan Stanley | 0.00% | No change | 168 | $338 |
| JPMorgan Chase & Co. | 0.00% | No change | 87 | $175 |
| Bank of America Corp. | 0.00% | Add +1.4% | 74 | $149 |
| SBI Securities Co., Ltd. | 0.00% | Add +4.0% | 52 | $105 |
| Harbour Investments, Inc. | 0.00% | No change | 50 | $101 |
"% of holder's portfolio" is SABS's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. the manager owns.